Safety profile
A well-established safety profile with KISQALI + ET *(1–4)
Real-world and diverse population studies confirm that KISQALI is well tolerated with a consistent safety profile in a broad range of HR+/HER2– ABC patients. (2,3)
Any grade
Grade 3/4
Neutropenia†
Leukopenia
Anaemia
Nausea
Fatigue
Diarrhoea
Vomiting
Liver-related AEs
QTcF prolongation
Percentage (%)
0
10
20
30
40
50
60
70
80
* Please consult your local Summary of Product Characteristics for the full KISQALI safety and tolerability profile.
† Febrile neutropenia was reported in 1.7% of patients exposed to KISQALI in the phase III clinical studies. (1)